Abbott Laboratories (ABT)
| Market Cap | 182.66B |
| Revenue (ttm) | 40.11B |
| Net Income (ttm) | 5.72B |
| Shares Out | 1.74B |
| EPS (ttm) | 3.26 |
| PE Ratio | 32.29 |
| Forward PE | 22.61 |
| Dividend | $2.20 (2.09%) |
| Ex-Dividend Date | Apr 12, 2024 |
| Volume | 5,964,673 |
| Open | 106.50 |
| Previous Close | 105.90 |
| Day's Range | 104.47 - 107.03 |
| 52-Week Range | 89.67 - 121.64 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 124.33 (+18.11%) |
| Earnings Date | Apr 17, 2024 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2023, ABT's revenue was $40.11 billion, a decrease of -8.12% compared to the previous year's $43.65 billion. Earnings were $5.72 billion, a decrease of -17.45%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $124.33, which is an increase of 18.11% from the latest price.
News
Abbott Labs Stock Falls as Q2 Guidance Outweighs Earnings Beat
Shares of Abbott Laboratories (ABT) fell in intraday trading Wednesday, with second-quarter guidance seeming to outweigh first-quarter results that beat analyst estimates.
Abbott beats estimates, reports a 2.2% rise in Q1 sales
Abbott Laboratories on April 17 reported a 2.2% rise of $10 billion in its 2024 first-quarter sales which includes the impact of the anticipated decline in COVID-19 testing-related sales as compared t...
Abbott Labs Stock Is Slipping. Disappointing Guidance Trumps a Strong Quarter.
Healthcare-products firm Abbott Laboratories' first-quarter earnings beat expectations, but second-quarter guidance was light.
Abbott Labs first-quarter results top estimates amid strong medical device sales
Abbott Laboratories on Wednesday reported first-quarter sales and profit that topped expectations amid strength in its medical-device business. The healthcare-products company reported first-quarter n...
Abbott beats quarterly profit estimates on strong medical device sales
Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its forecast, as robust demand for medical procedures boosted sales of its devices, includi...
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sa...
After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1?
Abbott (NYSE: ABT) will report its Q1 2024 results on Wednesday, April 17. We expect the company to post revenue of $9.9 billion and earnings of $0.95 on a per share and adjusted basis, aligning with ...
US FDA approves Abbott's heart valve repair device
Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device designed for patients at risk of complications or death during open-heart surgeries.
Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery More than 1.6 million people in the U.S. ar...
Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside
The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussion The test produces lab-qual...
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.
Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes
Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results wer...
What's Next For Abbott Stock After A 6% Rise This Year?
Abbott (NYSE: ABT) reported its Q4 results last month, with revenues above and earnings aligning with the street estimates. The company reported revenue of $10.24 billion and earnings of $1.19 on a pe...
Daily Dividend Report: Humana, Fedex, Honeywell, Coca-Cola, Abbott
Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on M...
Abbott Declares 401st Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
Abbott's heart valve repair device gets FDA advisers' backing
Advisers to the U.S. Food and Drug Administration on Tuesday backed an approval for Abbott Laboratories' heart valve repair device that is designed for patients who are at risk of complications or dea...
Abbott Laboratories says FDA independent panel votes to approve heart device
Abbott Laboratories ABT, -1.06% said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip.
FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve
Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U...
US FDA staff raises no new concerns about Abbott's heart device
The U.S. Food and Drug Administration (FDA) staff reviewers did not raise any new concerns on Friday over the safety and effectiveness of Abbott's heart valve repair device designed for patients who a...
Abbott Labs must face lawsuit over PediaSure height claims
A judge has rejected Abbott Laboratories' effort to dismiss a New York City grandmother's lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinicall...
New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again
Mixed reality experience allows blood donors to visit a digital world while remaining fully aware of their surroundings for a safe, relaxing donation 68.4% of pilot study participants who reported pre...
Drugmaker Abbott India's Q3 profit rises on strong demand
Pharmaceutical firm Abbott India reported a 26% rise in third-quarter profit on Thursday, as higher sales outpaced the impact of a pricing cap on certain medicines.
Abbott launches protein shake brand to help people on weight-loss drug
Abbott Laboratories said on Wednesday it has launched a new protein shake that would help adults looking to lose weight and maintain their muscle mass.
Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey
The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed m...
Jim Cramer just bought Abbott stock: should you too?
A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer's bullish view on Abbott stock His Charitable Trust bought...